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Purpose: To elucidate the clinical and epidemiologic characteristics of optic neuritis in Japan.
Design: Multicenter cross-sectional, observational cohort study.
Participants: A total of 531 cases of unilateral or bilateral noninfectious optic neuritis identified in 33
institutions nationwide in Japan.
Methods: Serum samples from patients with optic neuritis were tested for antieaquaporin-4 antibodies
(AQP4-Abs) and antiemyelin oligodendrocyte glycoprotein antibodies (MOG-Abs) using a cell-based assay and
were correlated with the clinical findings.
Main Outcome Measures: Antibody positivity, clinical and radiologic characteristics, and visual outcome.
Results: Among 531 cases of optic neuritis, 12% were AQP4-Ab positive, 10% were MOG-Ab positive, 77%
were negative for both antibodies (double-negative), and 1 case was positive for both antibodies. Pretreatment
visual acuity (VA) worsened to more than a median 1.0 logarithm of the minimum angle of resolution (logMAR) in
all groups. After steroid pulse therapy (combined with plasmapheresis in 32% of patients in AQP4-Abepositive
group), median VA improved to 0.4 logMAR in the AQP4-Abepositive group, 0 logMAR in the MOG-Abepositive
group, and 0.1 logMAR in the double-negative group. The AQP4-Abepositive group showed a high proportion of
females, exhibited diverse visual field abnormalities, and demonstrated concurrent spinal cord lesions on
magnetic resonance imaging (MRI) in 22% of the patients. In the MOG-Abepositive group, although posttreat-
ment visual outcome was good, the rates of optic disc swelling and pain with eye movement were significantly
higher than those in the AQP4-Abepositive and double-negative groups. However, most cases showed isolated
optic neuritis lesions on MRI. In the double-negative group, 4% of the patients had multiple sclerosis. Multivariate
logistic regression analysis of all participants identified age and presence of antibodies (MOG-Ab and AQP4-Ab)
as significant factors affecting visual outcome.
Conclusions: The present large-scale cohort study revealed the clinicoepidemiologic features of noninfectious
optic neuritis in Japan. Antieaquaporin-4 antibodyepositive optic neuritis has poor visual outcome. In contrast,
MOG-Ab positive cases manifested severe clinical findings of optic neuritis before treatment, but few showed
concurrent lesions in sites other than the optic nerve and generally showed good treatment response with favorable
visual outcome. These findings indicate that autoantibody measurement is useful for prompt diagnosis and proper
management of optic neuritis that tends to become refractory. Ophthalmology 2019;126:1385-1398ª 2019 by the
American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).The previous large-scale nationwide epidemiologic survey
of optic neuritis in Japan, the Optic Neuritis Trial
Multicenter Cooperative Research Group Japan, dates
back to 1995. According to the Optic Neuritis Trial Multi-
center Cooperative Research Group Japan report, the inci-
dence of optic neuritis in Japan is estimated to be 1.03 per
100 000 population.1 Among 550 patients analyzed, the
male-to-female ratio was 1:1.22, 65.9% of the patients
were 14 to 55 years of age, 28.2% showed bilateral disease,
18.6% were recurrent cases, and 7.5% had a history of optic
neuritis in the contralateral eye. However, these data should
consider the situations at the time of survey: magnetic
resonance imaging (MRI) and genetic diagnosis for Leber’sª 2019 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.hereditary optic neuropathy were not widely available, and
neuromyelitis optica (NMO) was included as a subtype of
multiple sclerosis (MS). Epidemiologic studies of optic
neuritis in other countries report annual incidences
(per 100 000 population) of 0.942 in Finland,2 1.46 in
Sweden,3 and 1 in the United Kingdom.4 There is a slight
female preponderance worldwide.
In 2004, Lennon et al5 discovered antieaquaporin-4
antibodies (AQP4-Abs) as a pathogen of NMO and distin-
guished NMO as a completely different entity from MS.
Thereafter, AQP4-Ab seropositive cases of NMO were
found to be more severe and resistant to treatment.6 In
addition, recent reports have shown that among patients1385https://doi.org/10.1016/j.ophtha.2019.04.042
ISSN 0161-6420/19
Ophthalmology Volume 126, Number 10, October 2019with AQP4-Abenegative NMO, those with optic neuritis
showing good a response to treatment but a high recurrence
rate show positive results for antiemyelin oligodendrocyte
glycoprotein antibodies (MOG-Abs),7e11 which have revo-
lutionized the understanding of optic neuritis. Hence, there
is a necessity to update epidemiologic characteristics of
optic neuritis in Japan. In this regard, our study group
sought to reinvestigate the epidemiologic and clinical
characteristics of optic neuritis in Japan based on the neu-
roimmunologic background.
In this study,we analyzed a total of 531 cases of unilateral or
bilateral noninfectious optic neuritis identified at 33 institutions
nationwide in Japan.However, it should be noted that although
the sample was large and represented diverse geography in
Japan, this studywas not a population-based survey. The aimof
this study was to elucidate the frequencies and clinical features
ofAQP4-Abepositive optic neuritis,MOG-Abepositive optic
neuritis, or both, which are important causes of optic neuritis,
and to compare our data with data from abroad, with the ulti-
mate goal of establishing effective treatments and optimal
prophylaxis for recurrence in the future.Methods
Participants
Thirty-three facilities participated in this study, of which 30 were
ophthalmology centers and 3 were neurology centers. The facilities
were distributed nationwide from Hokkaido in the north to Kyushu
in the south, covering 20 of 47 prefectures of Japan, and were
affiliated hospitals of councilors of the Japanese Neuro-
ophthalmology Society. Development of the common consensus
contents of this research was led by Kitasato University and the
Japanese Neuro-Ophthalmology Society. Because the cases were
collected from 6 main regions in Japan divided by geography,
climate, and culture (Hokkaido, Tohoku, Kanto-Koshinetsu,
Chubu-Kansai, Chugoku-Shikoku, and Kyushu), we speculate
that the case series was a good representation of all patients with a
diagnosis of optic neuritis receiving care at medical institutions in
Japan. The research was approved by the ethics committee of
each participating university (representative: Kitasato University
B 14-228). All studies adhered to the tenets of the Declaration of
Helsinki. All participants provided informed consent.
A total of 571 Japanese patients with noninfectious optic
neuritis who sought treatment at the 33 facilities because of uni-
lateral or bilateral vision deterioration between April 2015 and
January 2018 were included, and serum samples were collected.
The diagnosis of optic neuritis was based on the following criteria:
(1) acute visual disturbance or visual field defect, (2) presence of a
relative afferent pupillary defect in unilateral cases, (3) reduced
critical fusion frequency, and (4) normal or swollen optic disc.
Patients with cataract, glaucoma, or retinal diseases were excluded.
Serum samples were collected before initiation of treatment and
assayed for AQP4-Ab and MOG-Ab by methods described below.
In this study, we analyzed and evaluated the findings of the
affected eyes in patients with unilateral optic neuritis and the eyes
that were affected more seriously (higher activity) in patients with
bilateral optic neuritis.
Antibody Assays
Presence of MOG-Ab was measured using a cell-based assay at
Kanazawa Medical University and Niigata University by an1386investigator (K.T.) masked to the clinical information of the pa-
tients, according to the method described previously.12 In brief, a
full-length human myelin oligodendrocyte glycoprotein cDNA
expression vector (a gift from Dr. M. Reindl, Innsbruck Medical
University, Innsbruck, Austria) was transfected into human em-
bryonic kidney 293 cells using Lipofectamine reagent (Invitrogen
Japan, Tokyo, Japan). Cell cultures were maintained in Dulbecco’s
modified Eagle’s medium (Sigma-Aldrich, Tokyo, Japan) supple-
mented with 10% fetal calf serum. Twelve hours after transfection,
the human embryonic kidney cells were fixed in 4% para-
formaldehyde in 0.1 M phosphate-buffered saline (pH, 7.4) for 20
minutes. Nonspecific binding was blocked with 10% goat serum in
phosphate-buffered saline. Thereafter, the cells were incubated
with patient sera diluted 1:50 in 0.02% Triton X-100/10% goat
serum in phosphate-buffered saline for 1 hour at room temperature,
followed by fluorescence-conjugated antiehuman immunoglobulin
G1 (dilution, 1:500; Dako Denmark, Glostrup, Denmark) for 1
hour. SlowFade Gold anti-fade reagent (Invitrogen) was then
applied to the slides, which were mounted and observed under a
fluorescence microscope (AxioVision; Carl Zeiss Microscopy,
Jena, Germany). The presence of green fluorescence on the cells
was scored as MOG-Ab seropositivity. Serum anti-AQP4 IgG
antibody levels were measured by a previously reported indirect
immunofluorescence assay using human embryonic kidney 293
cells transfected with an expression vector containing M23 human
aquaporin-4 cDNA.13
Clinical Parameters
At the same time, the clinical course survey reportswere collected.The
antibody status and clinical data were correlated to analyze the char-
acteristics of various types of optic neuritis. The group that showed
negative results for both AQP4-Ab and MOG-Ab was considered to
show idiopathic optic neuritis, but this group also included patients
with clinically definite MS (CDMS) and clinically isolated syndrome
(CIS),14e16 although none demonstrated optic neuropathy associated
with systemic sarcoidosis.17 Diagnosis of MS was conducted
carefully, chiefly by neurologists at individual centers. Clinically
definite MS was diagnosed according to the 2010 revisions to the
McDonald criteria.18 None of the patients with positive AQP4-Ab
and MOG-Ab results were diagnosed with CDMS or CIS.
Pretreatment visual acuity (VA) was defined as the worst data
(nadir) obtained before treatment during the study period. Post-
treatment VA was defined as the best VA obtained after treatment
during the study period.
As for the imaging conditions for MRI, gadolinium imaging
was used as far as possible.19 However, when contrast medium
could not be used because of contrast agent hypersensitivity and
other conditions, a short s inversion recovery sequence was used.
Whether ocular MRI, head MRI, or both were performed was
decided by the doctor in charge at an individual center. Only
ocular MRI was available for 41 patients, only head MRI was
available for 9 patients, and both were available for 403 patients.
Basically, patients were treated with steroid pulse therapy at a
dose of 1000 mg for 3 days, followed by tapering with oral
prednisolone starting from 40 to 60 mg. When there was no ther-
apeutic response, usually this treatment was repeated after an in-
terval of 4 days. Patients who did not respond to steroid pulse
therapy were given plasmapheresis in combination. Indication for
plasmapheresis and the timing of treatment were decided by indi-
vidual facilities.
Statistical Analyses
Statistical analyses were conducted using the statistics software
package JMP version 13 (SAS Institute, Inc, Cary, NC). For
Ishikawa et al  Features of Optic Neuritis in Japanstatistical analyses, VA was presented in logarithm of the minimum
angle of resolution (logMAR) units, where counting fingers (CF)
was converted to 2.6 logMAR, hand movements was converted to
2.9 logMAR, light perception was converted to 3.1 logMAR, and
no light perception was converted to 3.4 logMAR.20 For intergroup
comparisons, the Fisher exact test was used for nominal variables
and the Steel-Dwass test and Welch t test were used for continuous
variables, depending on the distribution in each group. Specifically,
the Fisher exact test was used to compare among AQP-4-
Abepositive, MOG-Abepositive, and double-negative groups
for the following variables (all proportions of patients): women,
pretreatment VA of CF or worse, optic disc swelling, pain during
eye movement, visual field abnormalities, treatment with steroid,
posttreatment VA of CF or worse, posttreatment VA of 0.5 or
more, posttreatment VA of 0.2 or more, autoantibodies other than
AQP4-Ab and MOG-Ab, optic nerve swelling on MRI, sites of
optic nerve lesion on MRI, and length of optic nerve lesion on
MRI. The Steel-Dwass test was used to compare age, age at onset,
pretreatment VA, and posttreatment VA among the 3 groups. The
Welch test was used to examine pretreatment and posttreatment
VA comparing presence versus absence of optic nerve swelling and
lesion length of one half or more versus less than one half. The
Student t test was used to compare age at onset between men and
women in each antibody group. A P value of less than 0.05 was
considered significant for 2-group comparisons. For 3-group
comparisons (AQP4-Ab vs. MOG-Ab vs. double-negative
groups), Bonferroni correction was conducted, and P < 0.016
(0.05/3) was considered significant. In addition, for all patients in
the 3 groups, Spearman’s rank correlation was used to analyze the
correlation between age and VA, and these were compared before
and after treatment. In addition, multivariate logistic regression
analysis was conducted to identify the factors influencing visual
outcome.
Results
Initially 571 patients diagnosed with noninfectious optic neuritis
were recruited. However, in 40 patients, the diagnosis was subse-
quently changed to ischemic, compressive, hereditary, or toxic
optic neuropathy, and these patients were excluded. Eventually,
531 patients were studied, and 531 blood samples were analyzed
for antibody serostatus. In addition, the number of patients in
various analyses as detailed below differed depending on the
testing conditions and status of entry in clinical course survey
reports.
Rates of Positive Results for AntieAquaporin-4
Antibodies and AntieMyelin Oligodendrocyte
Glycoprotein Antibodies
Among 531 serum samples analyzed, 66 (12%) showed AQP4-
Abepositive results, 54 (10%) showed MOG-Abepositive re-
sults, 410 (77%) showed both AQP4-Abe and MOG-Abenegative
results (double-negative group), and 1 sample was both AQP4-
Abe and MOG-Abepositive (double-positive group). In the
double-negative group (n ¼ 410), 15 patients (4%) demonstrated
clinically definite MS and 18 patients (4%) demonstrated CIS
(Table 1).
Age and Male-to-Female Ratio
All the clinical parameters were compared among the AQP
4-Abepositive, MOG-Abepositive, and double-negative groups
(Table 1). There was no significant difference in median age
among the 3 groups. The proportion of female patients was 84%in the AQP4-Abepositive group and significantly higher than
in the MOG-Abepositive group (51%) and double-negative
group (64%; AQP4-Abepositive vs. MOG-Abepositive group,
P ¼ 0.0003, Fisher exact test; AQP4-Abepositive vs. double-
negative group, P ¼ 0.0014, Fisher exact test). In addition, when
comparing the mean onset ages of male and female patients in each
group, female patients were significantly older than male patients
in the AQP4-Abepositive group (55.8 years vs. 42.8 years;
P ¼ 0.024, Student t test). The distribution of patients’ ages at
onset is shown in Figure 1. The AQP4-Abepositive group showed
a trend of increase with age. The MOG-Abepositive group showed
biphasic peaks in the fourth and sixth decades of life groups. The
double-negative group showed a uniform distribution among
almost all age groups. The youngest patient, 3 years of age, was in
the MOG-Abepositive group, and the oldest patient, 84 years of
age, was in the AQP4-Abepositive group.
Pretreatment Visual Acuity
Visual acuity in the AQP4-Abepositive group was lower compared
with the double-negative group (2.6 vs. 1.2; P< 0.0001, Steel-Dwass
test; Table 1). In addition, 53% of patients in the AQP4-Abepositive
group showed a VA of CF or worse, and the percentage was signifi-
cantly higher than in the MOG-Abepositive and double-negative
groups (25% and 22%, respectively; AQP4-Abepositive vs. MOG-
Abepositive group,P¼ 0.008, Fisher exact test; AQP4-Abepositive
vs. double-negative group, P < 0.0001, Fisher exact test).
Optic Disc Swelling and Pain during Eye
Movement at Presentation
In the MOG-Abepositive group, the frequencies of optic disc
swelling (76%) and pain during eye movement or orbital pain
(77%) were both significantly higher compared with the AQP4-
Abepositive group (34% and 53%, respectively) and double-
negative group (46% and 46%, respectively; MOG-Abepositive
vs. AQP4-Abepositive group, P < 0.0001 and P ¼ 0.0148,
respectively, Fisher exact test; MOG-Abepositive vs. double-
negative group, P ¼ 0.0002 and P ¼ 0.0001, respectively, Fisher
exact test; Table 1).
Visual Field Abnormalities
In the MOG-Abepositive group, the vast majority (95%) of the
patients demonstrated central scotoma or complete visual field loss.
However, in the AQP4-Abepositive optic neuritis group, the pa-
tients not only demonstrated central scotoma but also various
patterns of visual field abnormalities (Table 1).
Treatments
Methylprednisolone pulse therapy was administered in 82% of all
patients in this study: 89% in the AQP4-Abepositive group, 86%
in the MOG-Abepositive group, and 80% in the double-negative
group. Furthermore, plasmapheresis was added to pulse steroid
therapy in 32% of the patients in the AQP4-Abepositive group.
All patients who underwent plasmapheresis were treated with pulse
steroid therapy in combination (Table 1).
Posttreatment Visual Acuity
There was no significant difference in posttreatment VA among
the 3 groups (Table 1). However, in the AQP4-Abepositive
group, 22% of the patients showed posttreatment VA of CF or
worse, and this proportion was significantly higher compared
with the double-negative group (8%; P ¼ 0.0051, Fisher exact
test). In the MOG-Abepositive group, VA recovered to1387
Table 1. Serostatus of AntieAquaporin-4 Antibody and AntieMyelin Oligodendrocyte Glycoprotein Antibody in Japanese Patients with Optic Neuritis and Comparison of Clinical
Parameters among 3 Groups
Total (n [ 531, Including
1 Double-Positive Patient)
AntieAquaporin-4
AntibodyePositive
Group
AntieMyelin
Oligodendrocyte
Glycoprotein
AntibodyePositive
Group
Double-Negative
Group*
P Valuey
Statistical
Method
AntieAquaporin-4
AntibodyePositive
Group vs.
AntieMyelin
Oligodendrocyte
Glycoprotein
AntibodyePositive
Group
AntieAquaporin-4
AntibodyePositive
Group vs.
Double-Negative
Group
AntieMyelin
Oligodendrocyte
Glycoprotein
AntibodyePositive
Group vs.
Double-Negative Group
No. of antibody positive/total no. of samples (%) 66/531 (12) 54/531(10) 410/531 (77) 0.2448 <0.0001z <0.0001z Fisher exact test
Age (yrs), median (range) 52.5 (13e84) 47.0 (3e82) 47.5 (4e87) 0.0981 0.1253 0.5269 Steel-Dwass test
No. of females/total (%) 52/62 (84) 25/49 (51) 247/388 (64) 0.0003z 0.0014z 0.0883 Fisher exact test
Age at onset, mean  SD (no. of patients/total)
Male 42.821.9 (10/62) 41.122.2 (24/49) 49.615.8 (139/388) 0.9874 0.4651 0.1622 Steel-Dwass test
Female 55.815.1 (52/62) 48.418.8 (25/49) 48.120.3 (245/388) 0.2551 0.0368z 0.9999 Steel-Dwass test
P value, Student t test 0.0241x 0.2159 0.4586
Pretreatment VA, median (IQR) 2.6 (1.2e3.1) (n ¼ 59) 1.6 (0.7e2.5)
(n ¼ 44)
1.2 (0.5e2.0)
(n ¼ 357)
0.1431 <0.0001z 0.2646 Steel-Dwass test
Proportion of pretreatment VA CF or worse,
no. of patients/total (%)
31/59 (53) 11/44 (25) 80/357 (22) 0.0080z <0.0001z 0.7043 Fisher exact test
Optic disc swelling, no. of patients/total (%) 21/61 (34) 34/45 (76) 166/361 (46) <0.0001z 0.0968 0.0002z Fisher exact test
Pain during eye movement, no. of patients/total (%) 31/59 (53) 36/47 (77) 161/347 (46) 0.0148z 0.4004 0.0001z Fisher exact test
Visual field, no. of patients/total (%)
Complete visual field loss 14/55 (26) 9/41 (22) 45/311 (15) 0.8101 0.0478 0.2467 Fisher exact test
Central scotoma 25/55 (46) 30/41 (73) 194/311 (61) 0.0074z 0.0246 0.2267 Fisher exact test
Temporal hemianopia 4/55 (7) 0/41 (0) 12/311 (4) 0.2122 0.4331 0.4111 Fisher exact test
Altitudinal hemianopia 12/55 (22) 1/41 (2) 46/311 (15) 0.0145z 0.2276 0.0522 Fisher exact test
Nasal hemianopia 0/55 (0) 1/41 (2) 14/311 (5) 0.8822 0.2328 0.8685 Fisher exact test
Treatment, no. of patients/total (%)
Pulse steroid only 32/56 (57) 35/42 (83) 247/333 (74) 0.0081z 0.0153z 0.2554 Fisher exact test
Plasmapheresis þ pulse steroid 18/56 (32) 1/42 (2) 19/333 (6) 0.0002z <0.0001z 0.5897 Fisher exact test
Observation 6/56 (11) 6/42 (14) 67/333 (20) 0.7571 0.1370 0.5343 Fisher exact test
Posttreatment VA
Median (IQR) 0.398 (e0.079 to 2)
(n ¼ 54)
0 (e0.079 to 0.523)
(n ¼ 39)
0.097 (e0.079 to 1)
(n ¼ 314)
0.0244 0.1286 0.1082 Steel-Dwass test
CF or worse, no. of patients/total (%) 12/54 (22) 2/39 (5) 25/314 (8) 0.0476 0.0051z 0.7577 Fisher exact test
0.5, no. of patients/total (%) 30/54 (56) 32/39 (82) 215/314 (69) 0.0082z 0.0849 0.0960 Fisher exact test
0.2, no. of patients/total (%) 24/54 (44) 29/39 (74) 176/314 (56) 0.0056z 0.1390 0.0380 Fisher exact test
Autoantibodies other than AQP4-Ab and
MOG-Ab, no. of patients/total (%)
Antinuclear antibody (þ) 16/49 (33) 7/35 (20) 65/272 (24) 0.2249 0.2123 0.6780 Fisher exact test
SS-A-Ab (þ) 8/46 (17) 0/28 (0) 7/238 (3) 0.0511 0.0007z 0.7675 Fisher exact test
SS-B-Ab (þ) 1/45 (2) 0/28 (0) 2/234 (1) 0.8095 0.9797 0.5107 Fisher exact test
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Ishikawa et al  Features of Optic Neuritis in Japan0.5 (decimal VA, 0.3) or higher in 82% of the patients and
0.2 (decimal VA, 0.7) or higher in 74%. The rate of recovery to
0.5 or more was significantly higher in the MOG-Abepositive
group than in the AQP4-Abepositive group (82% vs. 56%;
P ¼ 0.0082, Fisher exact test).Autoantibodies Other Than AntieAquaporin-4
Antibodies and AntieMyelin Oligodendrocyte
Glycoprotein Antibodies
When positive rates of autoantibodies other than AQP4-Ab and
MOG-Ab were compared among the 3 groups, the positive rate for
anti-Sjögren’s syndrome-related antigen A (SS-A) antibody was
significantly higher in the AQP4-Abepositive group than in the
double-negative group (17% vs. 3%; P ¼ 0.0007, Fisher exact
test). In the MOG-Abepositive group, none of the patients showed
positive results for SS-A antibody or anti-Sjögren’s syndrome type
B antibody (Table 1).Magnetic Resonance Imaging Findings
The frequency of optic nerve swelling on MRI was significantly
higher in the MOG-Abepositive group than in the double-negative
group (91% vs. 67%; P ¼ 0.0007, Fisher exact test; Table 2).
Regarding the lesion site, more patients in the AQP4-
Abepositive group showed posterior lesions, whereas more pa-
tients in the MOG-Abepositive group showed anterior lesions. In
both the AQP4-Abepositive and MOG-Abepositive groups, the
lengths exceeded one half of the intraorbital optic nerve length in
more than 60% of the lesions.
In the AQP4-Ab positive group, extraeoptic nerve lesions were
observed in the cerebral white matter, brainstem, and spinal cord;
in particular, concurrent spinal cord lesions were found in 8 pa-
tients (22%). Among these 8 patients, 1 patient showed longitu-
dinally extensive transverse myelitis. In the double-negative group,
lesions were found mainly in the cerebral white matter, but also in
the brainstem, spinal cord, and cerebellum. However, in the MOG-
Abepositive group, extraeoptic nerve lesions were found in only
3 patients: cerebral white matter lesion in 1 patient (2%) and spinal
cord lesion in 2 patients (8%).Effect of Optic Disc Swelling and Magnetic
Resonance Imaging Lesion Length on Visual
Acuity
In the AQP4-Abepositive group, patients with pretreatment optic
disc swelling showed significant improvement in posttreatment VA
compared with patients without optic disc swelling (0.071 vs. 1;
P ¼ 0.0443, Welch test; Table 3). Furthermore, in the double-
negative group, patients with pretreatment lesion length on MRI
exceeding one half of the intraorbital optic nerve length showed
significantly poorer VA both before (1.301 vs. 1; P ¼ 0.0211,
Welch test) and after (0.046 vs. e0.079; P ¼ 0.0106, Welch test)
treatment compared with patients with lesion length less than one
half of the intraorbital optic nerve length.Correlation between Age and Visual Acuity
Spearman’s rank correlation was conducted to examine the corre-
lation between age and VA using the data of all the patients
analyzed. The results showed that both pretreatment and post-
treatment VA decreased significantly as age increased (Fig 2).1389
Figure 1. Graphs showing distributions of patients by age at onset in each group. The antieaquaporin-4 antibody (AQP4-Ab)epositive rate tends to
increase with age until the fifth decade, followed by a plateau. The antiemyelin oligodendrocyte glycoprotein antibody (MOG-Ab)epositive rate shows a
biphasic distribution peaking in the fourth and sixth decades. The double-negative rate shows almost uniform distribution from the third to eighth decades.
y-axis ¼ antibody positive rate.
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Multivariate logistic regression analysis was conducted to identify
factors affecting the visual outcome using the data of all the pa-
tients analyzed. In model 1, age and presence or absence of anti-
bodies (AQP4-Ab and MOG-Ab) were used as explanatory
variables. In model 2, in addition to age and antibody status, lesion
length on MRI and presence or absence of the optic disc swellings
were included as explanatory variables (Table 4).
For model 1, in the first case, when posttreatment VA remained
worse than CF, the odds ratio for recovery to CF decreased by
0.97-fold with a 1-year increase in age, and furthermore, the
presence of AQP4-Ab significantly impeded recovery. In the sec-
ond case, for recovery to posttreatment VA of 0.1 (decimal VA,
approximately 0.7), age again showed a significant effect
(decreased by 0.96-fold with 1-year increase in age), whereas the
presence of MOG-Ab significantly increased the odds ratio. For
model 2, age remained a significant factor in the both the first and
second cases above, with lesion length on MRI being extracted
additionally as a significant factor in the second case.One Patient with AntieMyelin Oligodendrocyte
Glycoprotein Antibodye and AntieAquaporin-4
AntibodyePositive (Double-Positive) Optic
Neuritis
In the present study, 1 patient with MOG-Abe and AQP4-
Abepositive (double-positive) optic neuritis was identified. The pa-
tient was a 24-year-old woman who lost light perception because of
optic neuritis in the right eye at 13 years of age. At 18 years of age, she
demonstrated optic neuritis in the left eye and was found to show1390AQP4-Abepositive results. Shewas treatedwith steroid pulse therapy
at 1000 mg/day for 3 days. After 3 courses, decimal VA recovered to
1.5. At 22 years of age, she visited the hospital again because of
recurrent left optic neuritis. Because the time of her visit was within
our study period, this patient was included in our study. Examination
of her blood sample revealed that she also showedMOG-Abepositive
results. For that episode, she received 2 courses of steroid pulse
therapy (1000 mg/day for 3 days per course) with inadequate
response. Subsequently, intravenous immunoglobulin therapy
improved VA. Thereafter, she has been observed while undergoing
treatment with a combination of steroid and immunosuppressant
(azathioprine) therapy. Apart from ocular findings, no other abnor-
malities were observed during follow-up.Discussion
Rates of AntieAquaporin-4 Antibodye and
AntieMyelin Oligodendrocyte Glycoprotein
AntibodyePositive Results
In the present study, 531 patients could be analyzed. Among
these patients, the AQP4-Abepositive rate was 12%, with
median age at onset of 53 years, and the MOG-Abepositive
rate was 10%, with median age at onset of 47 years. The
double-negative group occupied 77% and included 15 pa-
tients (4%) with clinically definite MS and 18 patients (4%)
with CIS. The median age at onset in the double-negative
group was 48 years, and there was no significant differ-
ence in age at onset among the 3 groups. The distribution
Table 2. Comparison of Magnetic Resonance Imaging Findings among the 3 Groups
Magnetic Resonance Imaging Findings
AntieAquaporin-4
AntibodyePositive
Group
AntieMyelin
Oligodendrocyte
Glycoprotein
AntibodyePositive
Group
Double-Negative
Group*
P Valuey
Statistical
Method
AntieAquaporin-4
AntibodyePositive
Group vs.
AntieMyelin
Oligodendrocyte
Glycoprotein
AntibodyePositive Group
AntieAquaporin-4
AntibodyePositive
Group vs.
Double-Negative Group
AntieMyelin
Oligodendrocyte
Glycoprotein
AntibodyePositive
Group vs.
Double-Negative Group
Optic nerve swelling 42/51 (82)z 39/43 (91) 209/314 (67) 0.3856 0.0232 0.0007x Fisher exact test
Site of optic nerve lesion
Anterior 9/37 (24) 14/32 (44) 75/185 (41) 0.1249 0.0666 0.8460 Fisher exact test
Posterior 18/37 (49) 7/32 (22) 82/185 (44) 0.0257 0.7181 0.0194 Fisher exact test
Entire length 10/37 (27) 11/32 (34) 28/185 (15) 0.6030 0.0946 0.0218 Fisher exact test
Optic chiasma (overlap in some cases) 5/50 (10) 3/39 (8) 17/313 (6) 0.9967 0.2053 0.8349 Fisher exact test
Length of optic nerve lesion
Long (more than half of orbital length) 24/36 (67) 20/33 (61) 88/187 (47) 0.6254 0.0443 0.1868 Fisher exact test
Short (less than half of orbital length) 12/36 (33) 13/33 (39) 99/187 (53) 0.6254 0.0443 0.1868 Fisher exact test
Site of extraoptic nerve lesion
Cerebral cortex lesion 5/51 (10) 1/42 (2) 50/321 (16) 0.3049 0.3950 0.0377 Fisher exact test
Brainstem lesion 3/50 (6) 0/37 (0) 16/309 (5) 0.3565 0.9202 0.3158 Fisher exact test
Spinal cord lesion 8/36 (22) 2/26 (8) 19/191 (10) 0.2360 0.0488 0.9909 Fisher exact test
Cerebellum lesion 0/50 (0) 0/37 (0) 9/305 (3) d 0.4562 0.6064 Fisher exact test
*Negative results for antieaquaporin-4 antibody and antiemyelin oligodendrocyte glycoprotein antibody.
ySignificant at P < 0.016, Bonferroni correction for 3-group comparison.
zAll data are expressed as number with (positive) finding/total number tested (%).
xSignificant difference (P < 0.016).
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Table 3. Effects of Status of Disc Swelling and Magnetic Resonance Imaging Lesion Length on Visual Acuity
AntieAquaporin-4
AntibodyePositive Group
AntieMyelin Oligodendrocyte
Glycoprotein AntibodyePositive Group Double-Negative Group*
Effect of disc swelling on VA
Pretreatment VA, median (IQR) (no. of patients/total no.)
With optic disc swelling 1.699 (0.611e3.1) (21/59) 1.523 (0.73e2) (32/43) 1.222 (0.533e2.499) (161/349)
Without optic disc swelling 2.9 (1.398e3.1) (38/59) 2 (0.753e3.1) (11/43) 1.046 (0.567e2) (188/349)
P value 0.1553 0.6923 0.1763
Posttreatment VA
With optic disc swelling 0.071 (e0.079 to 1.165) (18/53) 0.079 (e0.079 to 0) (27/37) 0.046 (e0.079 to 0.730) (134/299)
Without optic disc swelling 1 (e0.079 to 2.9) (35/53) 0.097 (e0.079 to 0.567) (10/37) 0.097 (e0.079 to 1) (165/299)
P value 0.0443y 0.0877 0.7312
Effect of MRI lesion length on visual acuity
Pretreatment VA, median (IQR) (no. of patients/total no.)
Lesion length half or more 3 (0.523e3.4) (22/34) 1.097 (0.523e3.1) (19/32) 1.301(0.699e2.9) (87/184)
Lesion length less than half 2 (1.191e3.05) (12/34) 2 (1.261e3.15) (13/32) 1 (0.301e2) (97/184)
P value 0.7012 0.1546 0.0211y
Posttreatment VA
Lesion length half or more 1.023 (e0.02 to 3.025) (22/34) e0.079 (e0.079 to 0) (16/27) 0.046 (e0.079 to 1.242) (74/161)
Lesion length less than half e0.079 (e0.079 to 1) (12/34) 0.046 (e0.079 to 0.824) (11/27) e0.079 (e0.079 to 0.155) (87/161)
P value 0.1196 0.1756 0.0106y
IQR ¼ interquartile range; MRI ¼ magnetic resonance imaging; VA ¼ visual acuity expressed in logarithm of the minimum angle of resolution units.
*Negative results for antieaquaporin-4 antibody and antiemyelin oligodendrocyte glycoprotein antibody.
ySignificant difference, P < 0.05, Welch t test.
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portion of patients increased almost with increasing age in
the AQP4-Abepositive group, showed bimodal peaks in the
fourth and sixth decades of life in the MOG-Abepositive
group, and showed a peak in the fifth decade of life in the
double-negative group.
The proportion of female patients was 84% in the AQP4-
Abepositive group and significantly higher compared with
the other 2 groups. Gold et al21 reported that female gender
is a risk factor for demyelinated disease of the central
nervous system, including neuromyelitis optica spectrum
disorders. When the age at onset was compared by
gender, female patients showed significantly higher age at
onset only in the anti-AQP 4epositive group.
Jitprapaikulsan et al22 conducted a cross-sectional cohort
study analyzing 246 recurrent optic neuritis patients at the
Mayo Clinic between 2000 and 2017 and reported an
AQP4-Abepositive rate of 19% and MOG-Abepositive
rate of 13%. In a study of 109 patients with demyelinating
optic neuritis in China, 45 patients (41.3%) showed AQP4-
Abepositive results and 20 patients (18.3%) showed MOG-
Abepositive results, with a mean age at onset of 35.615.7
years in the AQP4-Abepositive optic neuritis group and
20.217.4 years in the MOG-Abepositive optic neuritis
group,23 showing a higher AQP4-Abepositive rate and a
tendency of younger onset compared with our findings.
However, a study from Denmark of 51 patients with acute
optic neuritis reported that 20 patients demonstrated MS at
follow-up, none showed positive results for AQP4-Ab, and
2 showed positive results for MOG-Ab.24 Furthermore, a
study in Thailand reported that among 150 patients
with optic neuritis, 58 patients (38.7%) showed NMO,
23 patients (15.3%) showed MS, and 69 patients (46.0%)
showed idiopathic disease.25 The above studies were1392conducted in specialized institutions, and the study
populations presumably vary because of racial differences
and contained a large proportion of severe cases of
disease. Our present multicenter collaborative study
included facilities with neuro-ophthalmologists. Hence,
there is a high possibility that a homogeneous study popu-
lation of optic neuritis was collected.
The prevalence of an AQP4-Abepositive NMO and
NMO spectrum disorder (NMOSD) in Japan is estimated to
be 2 to 4 per 100 000 population, and NMO occupies 27%
to 28% of inflammatory demyelinating disease of the central
nervous system in Japanese persons compared with 1% to
2% among white persons in Western countries.26,27 In a
report from South Korea, among 270 patients with inflam-
matory demyelinating disease, 18.1% showed AQP4-
Abepositive results and 6.3% showed MOG-Abepositive
results, whereas no patients with positive results for both
antibodies were found.28
Furthermore, although there is no accurate investigation
in Japan of the percentage of MS as an cause of optic
neuritis, the Optic Neuritis Treatment Trial (ONTT) in the
United States found that among 389 patients with optic
neuritis, 50% progressed to MS during a follow-up period of
15 years.29 Although the present study design differs from
the 15-year long-term follow-up observation of the ONTT
study, the contribution of MS as a cause of optic neuritis
may be lower in Japan compared with Western countries. In
our double-negative group, the prevalence of CDMS and
CIS was low, but a higher percentage of patients showed
cerebral white matter lesions. In this group, the number of
patients converting to MS is anticipated to increase as
follow-up continues long term.
In this study, 1 patient with optic neuritis and positive
results for both MOG-Ab and AQP4-Ab (double-positive)
Figure 2. Scatterplots showing the relationship between age at onset and visual acuity analyzed by Spearman’s rank correlation. Both (A) pretreatment and
(B) posttreatment visual acuity decreases significantly as age increases. CF ¼ counting fingers; HM ¼ hand movements; LPþ ¼ light perception; logMAR ¼
logarithm of the minimum angle of resolution; LPe ¼ no light perception.
Ishikawa et al  Features of Optic Neuritis in Japanwas identified. Double-positive optic neuritis is rare, but 2
reports of similar cases indicate poor prognosis.30,31 In the
present patient, it remains unknown which positive antibody
results appeared first. It is likely that the 2 antibodies with
different pathogenetic mechanisms synergistically worsen
visual functions.Table 4. Logistic Regression Analysis of Factors I
Variable Simple Regression
Visual acuity worse than CF
Age 0.968 (0.950‒0.987), 0.0012*
AQP4-Ab: þ/e 0.290 (0.137‒0.615), 0.0013*
MOG-Ab: þ/e 2.068 (0.479‒8.930), 0.3303
Lesion length on MRI: long/short 0.346 (0.130‒0.921), 0.0251y
Optic disc swelling: þ/e 0.948 (0.476‒1.901), 0.8788
Visual acuity worse than 0.1 logMAR (approximate decimal equivalent, 0.7)
Age 0.962 (0.950‒0.973),＜0.0001z
AQP4-Ab: þ/e 0.578 (0.322‒1.026), 0.0612
MOG-Ab: þ/e 2.436 (1.190‒5.392), 0.0140y
Lesion length on MRI: long/short 0.450 (0.251‒0.794), 0.0057*
Optic disc swelling: þ/e 1.665 (1.109‒2.511), 0.0139y
AQP4-Ab ¼ antieaquaporin-4 antibody; CF ¼ counting fingers; logMAR ¼
oligodendrocyte glycoprotein antibody; MRI ¼ magnetic resonance imaging; þ
Data are odds ratio (95% confidence interval), P value.
*P < 0.01.
yP < 0.05.
zP < 0.001.Optic Disc Swelling and Pain during Eye
Movement
In the present results, optic disc swelling was found in
76% of MOG-Abepositive optic neuritis patients, 34% of
AQP4-Abepositive patients, and 46% of double-negativenfluencing Visual Outcome of Optic Neuritis
Model 1 Model 2
0.970 (0.951‒0.989), 0.0026* 0.963 (0.935‒0.989), 0.0044*
0.336 (0.157‒0.749), 0.0058* 0.350 (0.125‒1.021), 0.0544
1.507 (0.417‒9.675), 0.5906 0.971 (0.223‒6.802), 0.9720
d 0.405 (0.132‒1.109), 0.0794
d 1.057 (0.385‒2.946), 0.9147
0.963 (0.951‒0.974), <0.0001z 0.964 (0.947‒0.980), <0.0001z
0.743 (0.401‒1.366), 0.3395 0.551 (0.244‒1.241), 0.1492
2.287 (1.067‒5.269), 0.0404y 1.077 (0.397‒3.169), 0.8875
d 0.465 (0.242‒0.879), 0.0183y
d 1.475 (0.769‒2.859), 0.2420
logarithm of the minimum angle of resolution; MOG-Ab ¼ antiemyelin
¼ positive; e ¼ negative; d ¼ not done.
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Abepositive group compared with the other 2 groups.
These results, together with the results of MRI to be
described later, suggest that the major site of inflammation
in MOG-Abepositive optic neuritis is the proximal part of
the optic nerve, that is, the anterior intraorbital portion,
whereas inflammation in AQP4-Abepositive optic neuritis
does not usually spread to the proximal part of the optic
nerve. In a Japanese study reported in 1999, 50% of idio-
pathic optic neuritis patients showed optic disc swelling.32
Furthermore, in the earlier report of the ONTT (1991) in
the United States, optic disc swelling was observed in
35.3%.33 In a later report of the ONTT (2008), optic disc
swelling was associated with a significantly lower
likelihood of MS developing. Therefore, the presence or
absence of optic disc swelling is a very important finding.
In a report of the ONTT (1991), pain during eyemovement
was found in 92.2% of optic neuritis patients.33 However,
previous reports from Japan show that the rate of pain
during eye movement is 57% in optic neuritis overall32 and
51% in AQP4-Abepositive optic neuritis,34 which are
lower rates compared with the United States report. In the
present study, the highest rate of pain during eye movement
of 77% was found in the MOG-Abepositive group, and the
rate was almost the same as that of optic disc swelling in
the same group. However, the report of the ONTT in 1991
showed no association between optic disc swelling and pain
during eye movement.33 Pain during eye movement is
related to retro-orbital lesions caused by traction of the
common tendinous ring, whereas periocular pain is presum-
ably trigeminal nerve distribution pain. Fazzone et al35
reported that pain during eye movement and periocular pain
in the trigeminal nerve distribution area were significantly
more frequent when the intraorbital segment of the optic
nerve was inflamed, whereas pain was less frequent when
inflammation was restricted to the canalicular or intracranial
segment.35
The MOG-Abepositive group manifested severe optic
disc and optic nerve swelling as well as strong inflammation
involving the orbital tissues around the optic nerve, sug-
gesting that pain during eye movement is intensified by the
effects from the dura sheath surrounding the optic nerve,
sclera, and intraorbital tissues through which the trigeminal
nerve is distributed and through traction of the extraocular
muscles in the common tendinous ring.
Visual Function and Treatment
Pretreatment VA was significantly lower in the AQP4-
Abepositive group than in the double-negative group.
Furthermore, the proportion of patients in the AQP4-
Abepositive group with VA of CF was significantly
higher compared with the other 2 groups. However, the VAs
were 2.6 logMAR, 1.6 logMAR, and 1.2 logMAR in the
AQP4-Abepositive, MOG-Abepositive, and double-
negative groups, respectively, and it is impossible to clini-
cally predict the presence or absence of AQP4-Ab and
MOG-Ab from VA at presentation alone.
For visual field defects, more than 95% in the MOG-
Abepositive group showed complete visual field loss or1394central scotoma, whereas the AQP4-Abepositive group
showed various types of visual field abnormalities,
including altitudinal hemianopia, nasal hemianopia, and
temporal hemianopia. Binocular vision loss resulting from
chiasmal lesions, bitemporal hemianopia, and homonymous
hemianopia36 or altitudinal hemianopia are relatively
common characteristics of NMO and NMOSD, whereas
they are rare in optic neuritis resulting from other causes.37
Regarding treatment, methylprednisolone pulse therapy
was administered in 80% of the patients in all 3 groups, and
plasmapheresis was used in combination in 32% of the
patients in the AQP4-Abepositive group. In the MOG-
Abepositive group, plasmapheresis was used in only 1
patient. These findings demonstrate that MOG-Abepositive
optic neuritis responds well to steroid pulse therapy. How-
ever, for the treatment of AQP4-Abepositive optic neuritis
in Japan, Endo et al34 report that methylprednisolone pulse
therapy is used an average of 3.34.1 times, indicating the
refractory nature of this disease. Clinicians should not
hesitate to add plasmapheresis in patients showing positive
AQP4-Ab results and inadequate response to steroid ther-
apy, aiming to recover or maintain visual function.38 In
particular, early use of plasmapheresis in AQP4-
Abepositive patients is reported to achieve good
outcomes.39
A report from Japan in 1995 shows that steroids are used
for the treatment of optic neuritis in more than 94% of the
facilities in Japan, and 30% of those facilities perform
methylprednisolone pulse therapy.1 In a survey conducted in
United States at approximately the same time, 35% of the
physicians replied that steroids are not used,40 which
highlighted the difference in treatment policy between
Japan and the United States. Recently, steroid pulse
therapy has become the mainstay of treatment for optic
neuritis because of its merits, including immediate effect
for recovery of visual function.
With respect to VA after treatment, the response to
treatment was evidently good in the MOG-Abepositive
group, with visual recovery to 0.5 (decimal VA, 0.3) or
higher in 82% of the patients and 0.2 (decimal VA, 0.7) or
higher in 74% of patients. Matsuda et al10 reported good
visual outcomes in MOG-Abepositive optic neuritis
patients. Furthermore, Zhao et al23 also reported good VA
outcomes after treatment in MOG-Abepositive optic
neuritis patients. However, although AQP4-Abepositive
optic neuritis patients recovered VA after treatment to 0.4,
VA remained CF or worse in 22% of patients. Likewise,
Jitprapaikulsan et al22 reported that both pretreatment and
posttreatment VA are poor in the AQP4-Abepositive
group, whereas visual outcomes are good in the MOG-
Abepositive group.
Autoantibodies Other Than AntieAquaporin-4
Antibody and AntieMyelin Oligodendrocyte
Glycoprotein Antibody
Nagaishi et al41 reported the coexistence of various
autoantibodies (antinuclear antibody, anti-SS-A and anti-
Sjögren’s syndrome type B antibody, antiethyroid
stimulating hormone receptor antibody, antithyroglobulin
Ishikawa et al  Features of Optic Neuritis in Japanantibody, and antiperoxidase antibody) other than AQP4-Ab
in patients with NMO. Furthermore, an association of the
presence of anti-SS-A antibody with AQP4-Abepositive
NMOSD has been reported.42 However, coexistence of
other autoantibodies with MOG-Ab is not common
compared with AQP4-Ab.23 The findings in the present
study show the same tendency as previous reports.
Magnetic Resonance Imaging Findings
In this study, the frequency of swollen optic nerve (inflam-
matory findings on MRI) was 91% in the MOG-Abepositive
group, 82% in the AQP4-Abepositive group, and 67% in the
double-negative group. In addition, the lesions tended to
involve the anterior portion of the optic nerve in MOG-
Abepositive optic neuritis and posterior portion of the optic
nerve in AQP4-Abepositive optic neuritis. These results are
in line with the above-mentioned finding of a high frequency
of optic disc swelling in the MOG-Abepositive group.
Furthermore, these findings are consistent with the MRI
characteristics of optic neuritis associated with AQP4-Ab,
MOG-Ab, and MS reported by Ramanathan et al.43 The
significantly lower frequency in the double-negative group
compared with the other 2 groups is probably because most
patients in this group showed idiopathic optic neuropathy,
which is characterized by mild and partial inflammation.
Moreover, in an MRI study of optic neuritis, compared with
recurrent MS patients, NMO patients showed longitudinally
extensive lesions extending from the posterior globe to the
optic tract, and at a cutoff lesion length of 17.6 mm, the
sensitivity and specificity for diagnosis of NMO were
improved. Conversely, MS lesions were more commonly
focal and localized in anterior intraorbital segment.44
In the studies of Akaishi et al,45,46 the lesion length of the
optic nerve in the acute phasewas significantly longer inMOG-
Abepositive optic neuritis patients compared with MS and
AQP4-Abepositive optic neuritis patients. Moreover, in
MOG-Abepositive optic neuritis patients, edema and
meandering of the optic nerve, as well as strong contrast
enhancement in orbital tissues around the optic nerve, were
observed.Also, the optic nerve lesion lengthmeasured onMRI,
especially the length anterior to the optic canal (from the
anterior orbit segment to optic canal), was a significant prog-
nostic factor for AQP4-Abepositive optic neuritis.45 However,
they reported that MOG-Abepositive optic neuritis is
characterized by intracranial lesions from the optic canal, and
this observation is contrary to our finding that an anterior
intraorbital lesion was dominant in MOG-Abepositive optic
neuritis. Thus, in optic neuritis, the lesion length not only
affects the visual outcome but is also an important factor that
may discriminate between NMO and MS depending on
certain conditions. Further detailed study is required.
Magnetic resonance imaging examination of sites other
than the optic nerve detected lesions in the cerebral white
matter, brainstem, and spinal cord in 10%, 6%, and 22%,
respectively, in the AQP4-Abepositive group: 16%, 5%,
and 10%, respectively, together with a cerebellar lesion in
3% in the double-negative group. However, there was only
1 cerebral lesion and 2 spinal cord lesions in the
MOG-Abepositive group. Based on these results, AQP4-Abepositive optic neuritis is more likely to show concur-
rent spinal cord abnormalities, whereas patients with
double-negative disease and MS show widely distributed
lesions in the cerebral white matter and cerebellum, and
MOG-Abepositive optic neuritis patients mostly show only
optic nerve lesions.
From the findings of the present study, MOG-Abepositive
optic neuritis showed optic nerve lesions onMRI in 91% of the
patients, but few radiologic findings were observed in other
sites, and althoughmanifesting severe optic neuritis in the early
stage, the visual outcome was favorable. In recent reports on
MOG-Abepositive disease, the proposal of treating this disease
as a distinct disease entity apart from MS and NMO is con-
spicuous.47,48 In fact, characteristics of MOG-Abepositive
optic neuritis similar to our findings have been reported from
Mayo Clinic and associated facilities49 and by Jarius et al.50
Kim et al28 also reported that MOG-Abepositive disease is
characterized by strong enhancement in soft tissues around
the optic nerve in 33% of patients and also enhancement
around the lateral ventricle in 30% of patients, with very low
frequency of spinal cord lesions compared with anti-
AQP4epositive disease. In addition, Sato et al8 reported the
characteristics of MOG-Abepositive NMOSD as having a
male preponderance, more optic nerve lesions than spinal
cord lesions, bilateral simultaneous optic neuritis, and good
recovery.
Factors Affecting Visual Outcome
No detailed reports have been published to date on age and
visual function in patients with optic neuritis. The present
study found no significant difference in age at onset among
the 3 groups. Furthermore, when all patients were analyzed,
a negative correlation was observed between age and VA
both before and after treatment. However, the pretreatment
distribution data do not show clearly that VA declines
significantly as age increases. Although posttreatment visual
recovery is apparently better in the second and third de-
cades, there are no definite data indicating that patients
beyond these age groups recover significantly.
Multivariate analysis of factors affecting visual function
using the entire study population statistically revealed that
age (accompanying age increase) and the presence of
AQP4-Ab adversely affected visual function, whereas the
presence of MOG-Ab improved visual function. For model
2, in addition to age and antibody status, lesion length on
MRI and optic disc swelling were included as explanatory
variables. In this analysis, only age showed a significant
effect on visual function, and the serostatus of antibodies
was no longer a significant factor. In the AQP4-
Abepositive group with poor visual outcome, 24 of 36
patients demonstrated lesion length on MRI exceeding one
half of the intraorbital optic nerve length. In the MOG-
Abepositive group with good visual outcome, 34 of 45
patients showed optic disc swelling. Considering these
findings along with the statistical results, the fact that AQP4-
Ab positivity and MOG-Ab positivity were extracted as
significant factors in model 1 but not in model 2 was the
result of the occurrence of significant offset effect, that is,
multicollinearity.1395
Ophthalmology Volume 126, Number 10, October 2019Limitations of This Study and Future Perspective
A limitation of this study is that although the sample
analyzed was large and drawn from diverse geography in
Japan, the study was not a population-based survey, and this
limitation may introduce bias into estimates drawn from our
data. Endo et al34 reported that in Japan, AQP4-
Abepositive optic neuritis recurs 1.52.3 times, and
46.8% of all patients show a bilateral decrease in VA. For
MOG-Abepositive optic neuritis also, a high percentage
of bilateral recurrent disease has been reported.10,22,23,51
Therefore, in evaluating optic neuritis, laterality and recur-
rence are very important findings. Of 531 patients analyzed
herein, 353 (66.5%) showed primary (first episode of) optic
neuritis, and long-term follow-up was not available for these
patients. Although the longest follow-up was 20 years, the
follow-up periods of the patients differed widely. The
medications used for prevention of relapse also varied
among facilities. Therefore, the results likely do not provide
a complete profile of optic neuritis in Japanese patients. We
are currently conducting studies on recurrence and laterality.
Furthermore, the number of patients diagnosed with MS was
small in this study. In the double-negative group, the
number of patients showing extraeoptic nerve lesions on
MRI was higher than the number with a diagnosis of CDMS
and CIS. In this respect, careful long-term follow-up,
including checking for conversion to MS, is required.
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